Department of Gastrointestinal Surgery, Jingzhou Central Hospital, the Clinical Second Clinical Medical College of Yangtze University, Jingzhou, Hubei, Renmin Road 1, Jingzhou, 434020, PR China.
Future Oncol. 2020 Jun;16(18):1289-1299. doi: 10.2217/fon-2020-0073. Epub 2020 May 7.
Clinical management of colorectal cancer is challenging. Circulating tumor cells (CTCs) and DNA (ctDNA) are investigated to detect key mutation and for prognosis for risk stratifications. 200 advance-stage patients with metastatic disease were selected and followed-up. Serial blood draws were used to quantify CTCs and ctDNA. Both CTCs and ctDNA are strongly associated with colorectal cancer patients. The positive predictive values were 96.5 and 96.3% among CTCs and ctDNA, respectively, for all 200 patients using mutation. Specificity for healthy controls was 100%. As a prognosis indicator, results demonstrated that patients who had positive CTCs and plasma DNA had worse outcomes. Blood-based assessment of colorectal cancer shows promising results in early-risk stratifications.
结直肠癌的临床管理具有挑战性。循环肿瘤细胞（CTCs）和 DNA（ctDNA）被用于检测关键突变，并进行预后风险分层。选择了 200 名患有转移性疾病的晚期患者进行随访。通过连续采血来定量 CTCs 和 ctDNA。CTCs 和 ctDNA 均与结直肠癌患者密切相关。在所有 200 名患者中，使用 突变，CTC 和 ctDNA 的阳性预测值分别为 96.5%和 96.3%。对健康对照的特异性为 100%。作为预后指标，结果表明，有阳性 CTCs 和血浆 DNA 的患者结局更差。结直肠癌的基于血液的评估在早期风险分层中显示出有前景的结果。
